Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ultragenyx Pharmaceu (NQ: RARE ) 55.55 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Sep 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Ultragenyx Pharmaceu < Previous 1 2 3 4 5 6 7 8 Next > RARE Stock Earnings: Ultragenyx Pharmaceutical Misses EPS, Misses Revenue for Q1 2024 May 02, 2024 RARE stock results show that Ultragenyx Pharmaceutical missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. Via InvestorPlace Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update May 02, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease April 30, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI) April 30, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Forecasting The Future: 11 Analyst Projections For Ultragenyx Pharmaceutical April 22, 2024 Via Benzinga Expert Outlook: Ultragenyx Pharmaceutical Through The Eyes Of 9 Analysts April 05, 2024 Via Benzinga Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update April 25, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) April 19, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire S&P 500 Down Over 1%; US Retail Sales Increase 0.7% In March April 15, 2024 U.S. stocks turned lower toward the end of trading, with the S&P 500 falling more than 1% on Monday. The Dow traded down 0.64% to 37,741.18 while the NASDAQ fell 1.68% to 15,902.96. The S&P 500 also... Via Benzinga Topics Stocks Exposures US Equities Analyst Scoreboard: 8 Ratings For Ultragenyx Pharmaceutical March 18, 2024 Via Benzinga Recap: Ultragenyx Pharmaceutical Q4 Earnings February 15, 2024 Via Benzinga The Latest Analyst Ratings For Ultragenyx Pharmaceutical February 15, 2024 Via Benzinga Earnings Scheduled For February 15, 2024 February 15, 2024 Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. Via Benzinga Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session April 15, 2024 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic... Via Benzinga Crude Oil Down 1%; Charles Schwab Sales Top Estimates April 15, 2024 U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow traded up 0.35% to 38,114.61 while the NASDAQ rose 0.07% to 16,187.02. The S&P... Via Benzinga Topics Stocks Exposures Fossil Fuels US Equities Preview: Ultragenyx Pharmaceutical's Earnings February 14, 2024 Via Benzinga Rare Disease-Focused-Ultragenyx Pharmaceutical Stock Falls On Serious Adverse Events In Eaarly Genetic Disorder Study April 15, 2024 New data from Phase 1/2 study of GTX-102 for Angelman syndrome shows rapid and sustained improvement in patients, exceeding natural history data. Via Benzinga Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session April 15, 2024 U.S. stock futures were higher this morning, with the Dow futures gaining over 200 points on Monday. Via Benzinga Topics Stocks Exposures US Equities Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102 April 15, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome April 12, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting April 12, 2024 Company will host investor call on April 17 at 8:00 a.m. ET to discuss new data from GTX-102 Phase 1/2 clinical study in patients with Angelman syndrome From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) March 22, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx to Participate at Investor Conferences in March February 27, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) February 23, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update February 15, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update February 08, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA) February 06, 2024 The latest data from the pivotal Transpher A and long-term follow-up studies will be presented at WORLDSymposium™ 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome February 05, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease January 25, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) January 19, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire < Previous 1 2 3 4 5 6 7 8 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.